Bicara Therapeutics Inc. Debt Securities, Available-for-sale, Amortized Cost
Bicara Therapeutics Inc. (BCAX) had Debt Securities, Available-for-sale, Amortized Cost of $401.23 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $401.23M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $216.53M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $317.87M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $236.05M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $401.23M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $216.53M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $317.87M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $236.05M 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |